Thermal waters as cosmeceuticals: La Roche-Posay thermal spring water example

La Roche-Posay Pharmaceutical Laboratories, Asnières, France.
Clinical, Cosmetic and Investigational Dermatology 01/2013; 6:23-8. DOI: 10.2147/CCID.S39082
Source: PubMed


The curative use of thermal spring water is well known, but further investigation of its biological properties and therapeutic benefits is necessary. This present article reports all available scientific data concerning La Roche-Posay Thermal Spring Water and provides a better understanding of the biological mechanism of action of this water in regard to its composition and physicochemical properties and its clinical benefits for patients. These data justify the use of this selenium-rich water as an active or "cosmeceutical" ingredient in topical formulations to increase quality of life and compliance in patients with chronic disease.

23 Reads
  • Source
    • "Indeed, other raw materials, with no filtering effect but which are present in the composition of a product, can contribute to this type of effect. We can mention for example thermal waters such as the one from La Roche Posay (Ghersetich et al., 2001; Seite, 2013), and also molecules such as allantoin, bisabolol and potassium glycyrrhizinate (Couteau et al., 2012b) (Fig. 2). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Given that previous studies have highlighted the anti-inflammatory nature, which is influenced by UV radiation, of a certain number of ultraviolet filters currently used in Europe, it seemed interesting to evaluate the persistence of this type of effect. The persistence of the anti-inflammatory effect of fourteen preparations, each containing one of the ultraviolet filters authorized by Regulation (CE) No. 1223/2009, and of 10 commercially-available sun products was studied using the phorbol-myristate-acetate test on mice, up to 6 and a half hours after application. We can observe that a benzophenone, oxybenzone, a PABA derivative, octyldimethylPABA and a derivative of cinnamic acid, OMC as well as 3 commercially-available products, display a very marked anti-inflammatory effect at the end of our experimentation phase. The type of effect observed could encourage users to prolong the time that they are exposed to the sun, due to there being no warning signs, namely sunburn.
    International Journal of Pharmaceutics 12/2014; 476(s 1–2):160–163. DOI:10.1016/j.ijpharm.2014.09.024 · 3.65 Impact Factor
  • Source
    • "La Roche-Posay (LRP), France, is a thermal spa particularly known to improve psoriasis and atopic dermatitis. Several publications have highlighted the effects on skin6 of its selenium-rich water (LRP-TSW), which particularly protects against the short-and long-term effects of reactive oxygen species induced by ultraviolet radiation as well as inflammation and irritation. A continuous process has previously developed to produce a biomass grown on LRP-TSW-enriched medium (LRP-VFB) and one objective of this study was to compare the biological activities of LRP-VFB and VFB. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Vitreoscilla filiformis (VF) biomass (VFB) has been widely used in cosmetic preparations and shown to modulate the major inducible free-radical scavenger mitochondrial superoxide dismutase in skin cells. By adding La Roche-Posay (LRP) thermal spring water to the VF culture medium, we obtained a biomass (LRP-VFB) with a similar mitochondrial superoxide dismutase activation capacity to VF. Also, the new biomass more powerfully stimulated mRNA expression and antimicrobial peptides in reconstructed epidermis. Interestingly, a predictive computer model that analyzed transducing events within skin epidermal cells suggested that this protective activity may involve the Toll-like receptor 2/protein kinase C, zeta transduction pathway. Protein kinase C, zeta inhibition was effectively shown to abolish VFB-induced gene stimulation and confirmed this hypothesis. This thus opens new avenues for investigation into the improvement of skin homeostatic defense in relation to the control of its physiological microbiota and innate immunity.
    Clinical, Cosmetic and Investigational Dermatology 08/2013; 6:191-6. DOI:10.2147/CCID.S47324
  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of these studies was to investigate whether a skincare product containing Ambophenol, Neurosensine, and La Roche-Posay thermal spring water formulated in a highly protective packaging can have an impact in the management of rosacea-prone skin subjects. Several studies were performed to evaluate the efficacy of this product in the management of rosacea prone skin, as either monotherapy or adjunctive therapy or to maintain the efficacy of a Metronidazole treatment. The first study was performed on 37 women aged 18-45 with added stage 2 erythro-couperosis, who applied test formula as monotherapy twice a day for 4 weeks. During a second study, a dermatological evaluation was performed on patients with stage I or II rosacea, a questionnaire containing information about patient characteristics, tolerance, clinical signs, symptoms and skin reactivity to "trigger factors" was completed by dermatologists at baseline and 2 months after treatment with the test formula as either monotherapy or adjunctive therapy. Finally, in a third study, 65 patients finishing a Metronidazole treatment applied once daily and the tested formula twice daily were divided into 2 groups using the test formula or vehicle control, twice a day for 8 weeks for the evaluation of efficacy as adjunctive therapy. We noted that the test formula, as an adjunctive therapy, helped prolong the efficacy of a Metronidazole treatment. In monotherapy, there was a significant efficacy of the test formula associated with an excellent tolerance. A significant improvement of all the clinical signs and symptoms of rosacea and a reduction of the skin reactivity to "trigger factors" were shown. These studies highlight the interest value and impact of a skincare product containing Ambophenol, Neurosensine, and La Roche-Posay thermal spring water formulated in a highly protective packaging in monotherapy or in combination with or after a therapeutic treatment in the management of patients suffering from rosacea. J Drugs Dermatol. 2013;12(8):920-924.
    Journal of drugs in dermatology: JDD 08/2013; 12(8):920-4. · 1.45 Impact Factor
Show more


23 Reads
Available from